October 01, 2026 10:04 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Flydubai cockpit attack: Injured Indian pilot Smit Machchhar airlifted to Abu Dhabi | India backs brave flydubai pilot Smit Machchhar, Ambassador meets family after cockpit attack | ‘Saved us from a 9/11’: PM Modi praises Captain Smit Machchhar after terrifying flydubai cockpit attack | 'India is proud': PM Modi hails Flydubai Captain Smit Machchhar as ‘hero’ after mid-air cockpit horror | ‘Too early to say’: Benjamin Netanyahu on Iran link to flydubai plane incident | ‘I didn’t wait, I ran’: Israeli dentist reveals how he saved wounded Flydubai captain during cockpit attack | Israel-bound flight lands in Saudi Arabia as pilots fight in cockpit, stabbing triggers hijack scare mid-air | Vimal ad row: SRK, Ajay Devgn, Tiger Shroff respond to FDA notices, says Tukaram Mundhe | Vijay’s TVK expands to Bengal? Party breaks silence on Purba Bardhaman office | ‘This guy is a monster’: Trump’s hilarious praise for Sundar Pichai, Google CEO’s witty reply

AstraZeneca to invest $50 billion in US, build largest factory in Virginia amid Trump tariff threats

| @indiablooms | Jul 22, 2025, at 08:40 pm

British pharmaceutical major AstraZeneca on Tuesday unveiled a $50 billion investment plan in the United States, which includes setting up a multi-billion-dollar manufacturing facility in Virginia—its largest single investment in manufacturing to date, according to media reports.

The move comes as the Trump administration escalates pressure on foreign pharmaceutical imports through proposed steep tariffs.

According to AFP, the company anticipates that half of its global revenue will come from the US by 2030, signalling a marked strategic pivot toward the American market.

“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals,” AstraZeneca CEO Pascal Soriot said in a statement.

The announcement coincides with US President Donald Trump intensifying his stance on imposing tariffs on drug imports—an area previously spared in earlier rounds of trade levies.

A White House-commissioned investigation is currently underway, and new duties could go as high as 200%, according to hints from the administration.

“For decades Americans have been reliant on foreign supply of key pharmaceutical products,” US Commerce Secretary Howard Lutnick was quoted as saying by AFP.

He added that the proposed measures are designed to “end this structural weakness” in the domestic pharmaceutical supply chain.

AstraZeneca’s Virginia facility is set to be the centrepiece of its expanded footprint in the US and mirrors a broader industry trend.

Several other global drugmakers—who had largely escaped tariffs for the last three decades—are also beginning to move investment and manufacturing to American soil.

Back in April, AstraZeneca had already revealed plans to shift part of its European manufacturing base to the US, even before the current tariff momentum took shape.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.